News & Updates
Filter by Specialty:
Electronic, mobile health interventions improve JIA management
Harnessing electronic (eHealth) and mobile health (mHealth) interventions appears to be an efficient way of supplementing the management of juvenile idiopathic arthritis (JIA), as shown by the results of a systematic review and meta-analysis.
Electronic, mobile health interventions improve JIA management
22 Mar 2022
Stroke in young donors tied to higher recipient mortality, allograft failure
Stroke, a common cause of donor brain death, exhibits a substantially different effect on recipient and allograft survival depending on the age of the donor, suggests a recent study. Among younger donors, stroke contributes to increased recipient mortality and allograft failure than other causes of brain death.
Stroke in young donors tied to higher recipient mortality, allograft failure
22 Mar 2022
ADT after radiotherapy does not worsen MACE risk
Androgen deprivation therapy (ADT) does not seem to aggravate the likelihood of major adverse cardiovascular events (MACEs) in prostate cancer patients after curative radiotherapy (RT), according to a recent Singapore study.
ADT after radiotherapy does not worsen MACE risk
22 Mar 2022
Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.
Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
22 Mar 2022
Pandemic contributes to poor mental, oral health
Oral health has been mildly compromised during the coronavirus disease 2019 (COVID-19) pandemic, particularly among people who have been infected and those suffering from depression, anxiety, and psychological stress, a recent study reported.
Pandemic contributes to poor mental, oral health
22 Mar 2022
Fulvestrant–sapanisertib combo shows modest benefit in advanced, metastatic breast cancer
Treatment with the combination of fulvestrant plus sapanisertib yields a numerical increase in progression-free survival in patients with ER-positive, HER2-negative advanced or metastatic breast cancer as compared with the use of fulvestrant alone, according to the results of a phase II trial. However, the combination is associated with increased toxicity.
